March 16, 2024Open Access

Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics

Key Points

Key points are not available for this paper at this time.

Abstract

Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Cantone et al. (Sat,) studied this question.

synapsesocial.com/papers/68e73b96b6db6435876b5018 https://doi.org/https://doi.org/10.1007/s00405-024-08548-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial2023 · 11 citations
2Parosmia after COVID-19: olfactory training, neuroinflammation and distortions of smell.2022 · 11 citations
3Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects2006 · 1,498 citations
4Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study2020 · 647 citations
5Sample Size Estimation in Clinical Research2020 · 447 citations

AI से पूछें

Bookmark

View Full Paper